share_log

Morgan Stanley Initiates Coverage On ProKidney With Equal-Weight Rating, Announces Price Target of $13

Morgan Stanley Initiates Coverage On ProKidney With Equal-Weight Rating, Announces Price Target of $13

摩根士丹利以同等权重评级启动对ProKidney的保险,宣布目标股价为13美元
Benzinga Real-time News ·  2022/11/10 08:02

Morgan Stanley analyst Vikram Purohit initiates coverage on ProKidney (NASDAQ:PROK) with a Equal-Weight rating and announces Price Target of $13.

摩根士丹利分析师维克拉姆·普罗希特以同等权重评级启动了对ProKidney(纳斯达克股票代码:PROK)的报道,并宣布目标股价为13美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发